secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001193125-23-145650
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics' COYA 301 shows improved cognition and Treg expansion in Phase 1 AD study
--------------------------------------------------------------------------------

- 8 AD patients treated with monthly COYA 301 (low-dose IL-2) showed statistically significant improvement in MMSE scores (p=0.015) during treatment.
- Treg percentage nearly doubled from 4.55% to 8.68% (p=0.0004); suppressive function increased from 46.6% to 79.5% (p=0.003).
- Blood levels of pro-inflammatory cytokines IL-15, CCL2, and CCL11 were significantly lowered after each treatment cycle.
- No serious adverse events; mild injection-site reactions and leukopenia; no patient discontinued the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523145650/0001193125-23-145650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523145650/d471671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-145650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer